SBI Securities Co. Ltd. Invests $333,000 in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

SBI Securities Co. Ltd. acquired a new position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the fourth quarter, HoldingsChannel reports. The firm acquired 49,273 shares of the company’s stock, valued at approximately $333,000.

A number of other hedge funds have also recently made changes to their positions in RXRX. ARK Investment Management LLC lifted its holdings in shares of Recursion Pharmaceuticals by 16.4% in the 3rd quarter. ARK Investment Management LLC now owns 32,769,186 shares of the company’s stock worth $215,949,000 after acquiring an additional 4,626,268 shares during the last quarter. State Street Corp increased its stake in shares of Recursion Pharmaceuticals by 47.1% in the third quarter. State Street Corp now owns 12,870,272 shares of the company’s stock worth $84,815,000 after buying an additional 4,120,685 shares during the period. Geode Capital Management LLC increased its stake in shares of Recursion Pharmaceuticals by 13.7% in the third quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company’s stock worth $35,803,000 after buying an additional 656,003 shares during the period. Institute for Wealth Management LLC. purchased a new position in shares of Recursion Pharmaceuticals in the fourth quarter worth $3,928,000. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Recursion Pharmaceuticals by 17.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,940,680 shares of the company’s stock worth $12,789,000 after buying an additional 288,926 shares during the period. 89.06% of the stock is currently owned by institutional investors.

Recursion Pharmaceuticals Stock Up 1.7 %

Shares of NASDAQ RXRX opened at $6.58 on Thursday. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals, Inc. has a 12 month low of $5.60 and a 12 month high of $12.36. The firm has a market capitalization of $2.57 billion, a PE ratio of -4.30 and a beta of 0.86. The firm has a fifty day simple moving average of $7.68 and a two-hundred day simple moving average of $7.08.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Friday, February 28th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.17). The company had revenue of $4.60 million during the quarter, compared to the consensus estimate of $19.04 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm’s revenue for the quarter was down 57.8% compared to the same quarter last year. During the same quarter last year, the company posted ($0.42) earnings per share. Equities analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently commented on RXRX shares. KeyCorp decreased their target price on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. Cowen reaffirmed a “hold” rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Leerink Partners decreased their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a report on Friday, February 28th. Finally, Needham & Company LLC restated a “buy” rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a report on Thursday, February 6th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $8.25.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.